Sign in or create an account to add this stock to your watchlist.
About NuCana (NASDAQ:NCNA)
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in preclinical studies for the treatment of solid tumors and hematological malignancies. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-22.28
Forward P/E Ratio-24.86
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$3.78 per share
Price / Book6.25
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
NuCana (NASDAQ:NCNA) Frequently Asked Questions
What is NuCana's stock symbol?
NuCana trades on the NASDAQ under the ticker symbol "NCNA."
What price target have analysts set for NCNA?
4 equities research analysts have issued 12-month target prices for NuCana's shares. Their predictions range from $23.00 to $25.00. On average, they expect NuCana's stock price to reach $24.00 in the next year. View Analyst Ratings for NuCana.
Who are some of NuCana's key competitors?
Some companies that are related to NuCana include Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO), Heron Therapeutics (HRTX), Acadia Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), OPKO Health (OPK) and Evotec A.G. (EVTCY).
Who are NuCana's key executives?
NuCana's management team includes the folowing people:
- Prof. Christopher B. Wood Ph.D., M.D., FRCS, Chairman & Chief Medical Officer (Age 72)
- Mr. Hugh S. Griffith, Founder, Chief Exec. Officer and Director (Age 50)
- Mr. Donald Munoz, CFO & Principal Accounting Officer (Age 49)
When did NuCana IPO?
(NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.
When did the company's lock-up period expire?
NuCana's lock-up period expired on Tuesday, March 27th. NuCana had issued 6,667,000 shares in its initial public offering on September 28th. The total size of the offering was $100,005,000 based on an initial share price of $15.00. Since the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
Has NuCana been receiving favorable news coverage?
News headlines about NCNA stock have trended somewhat positive on Monday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NuCana earned a media sentiment score of 0.10 on Accern's scale. They also assigned press coverage about the company an impact score of 46.39 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are NuCana's major shareholders?
NuCana's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sofinnova Ventures Inc (14.67%), Baillie Gifford & Co. (2.02%), Alps Advisors Inc. (0.13%), Asymmetry Capital Management L.P. (0.13%), Millennium Management LLC (0.04%) and Citadel Advisors LLC (0.04%). View Institutional Ownership Trends for NuCana.
Which institutional investors are selling NuCana stock?
Which institutional investors are buying NuCana stock?
NCNA stock was purchased by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Baillie Gifford & Co., Asymmetry Capital Management L.P. and Alps Advisors Inc.. View Insider Buying and Selling for NuCana.
How do I buy shares of NuCana?
Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NuCana's stock price today?
One share of NCNA stock can currently be purchased for approximately $23.62.
How big of a company is NuCana?
NuCana has a market capitalization of $751.38 million. The company earns $-29,750,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. NuCana employs 16 workers across the globe.
How can I contact NuCana?
NuCana's mailing address is 3 LOCHSIDE WAY, EDINBURGH X0, EH12 9DT. The company can be reached via phone at 44-0-13-1248-3660.
MarketBeat Community Rating for NuCana (NCNA)MarketBeat's community ratings are surveys of what our community members think about NuCana and other stocks. Vote "Outperform" if you believe NCNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NCNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
NuCana (NASDAQ:NCNA) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
NuCana (NASDAQ NCNA) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 30.76%
NuCana (NASDAQ NCNA) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
NuCana (NASDAQ NCNA) News Headlines
NuCana (NASDAQ:NCNA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NuCana (NASDAQ:NCNA) Income Statement, Balance Sheet and Cash Flow Statement
NuCana (NASDAQ NCNA) Stock Chart for Monday, May, 21, 2018